NO970264L - Pharmaceutical compositions comprising a chimeric TNF-binding protein - Google Patents

Pharmaceutical compositions comprising a chimeric TNF-binding protein

Info

Publication number
NO970264L
NO970264L NO970264A NO970264A NO970264L NO 970264 L NO970264 L NO 970264L NO 970264 A NO970264 A NO 970264A NO 970264 A NO970264 A NO 970264A NO 970264 L NO970264 L NO 970264L
Authority
NO
Norway
Prior art keywords
binding protein
pharmaceutical compositions
chimeric tnf
tnf
chimeric
Prior art date
Application number
NO970264A
Other languages
Norwegian (no)
Other versions
NO970264D0 (en
Inventor
Robert Frederick Geoffre Booth
Werner Lesslauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO970264D0 publication Critical patent/NO970264D0/en
Publication of NO970264L publication Critical patent/NO970264L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse er rettet mot anvendelse av et chimærisk TNF-bindende protein som omfatter en oppløselig del av den humane p55- eller p-75- TNF-reseptor og alt eller deler av de konstante domener av den tunge eller lette kjede av humant immunoglobulin eller et farmasøytisk akseptabelt salt derav for fremstilling av en farmasøytisk sammensetning for behandling av autoimmune sykdommer.The present invention is directed to the use of a chimeric TNF binding protein comprising a soluble portion of the human p55 or p-75 TNF receptor and all or part of the constant or light chain human immunoglobulin constant domain or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of autoimmune diseases.

NO970264A 1994-07-22 1997-01-21 Pharmaceutical compositions comprising a chimeric TNF-binding protein NO970264L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94111455 1994-07-22
PCT/EP1995/002788 WO1996003141A1 (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein

Publications (2)

Publication Number Publication Date
NO970264D0 NO970264D0 (en) 1997-01-21
NO970264L true NO970264L (en) 1997-03-24

Family

ID=8216138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970264A NO970264L (en) 1994-07-22 1997-01-21 Pharmaceutical compositions comprising a chimeric TNF-binding protein

Country Status (11)

Country Link
EP (1) EP0772449A1 (en)
JP (1) JPH09508140A (en)
AU (1) AU3111995A (en)
BR (1) BR9508419A (en)
CA (1) CA2195665A1 (en)
CZ (1) CZ283219B6 (en)
FI (1) FI970247A0 (en)
HU (1) HUT76666A (en)
NO (1) NO970264L (en)
PL (1) PL318501A1 (en)
WO (1) WO1996003141A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
JP2000510113A (en) * 1996-05-08 2000-08-08 エフ・ホフマン―ラ ロシュ アーゲー Treatment of asthma with TNFR-Ig
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
CA2272822A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
DE69911641T2 (en) 1998-11-27 2004-08-05 Synaptics (Uk) Ltd., Harston POSITION SENSOR
EE200300408A (en) 2001-02-23 2003-12-15 Immunex Corporation Increasing the yield of active proteins
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
AU2003209755B2 (en) 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
EP1132471A3 (en) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-binding proteins
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
CA2147180A1 (en) * 1992-10-15 1994-04-28 Gokhan S. Hotamisligil Treatment of insulin resistance in obesity linked type ii diabetes using antagonists to tnf-.alpha. function

Also Published As

Publication number Publication date
AU3111995A (en) 1996-02-22
FI970247A (en) 1997-01-21
WO1996003141A1 (en) 1996-02-08
EP0772449A1 (en) 1997-05-14
FI970247A0 (en) 1997-01-21
NO970264D0 (en) 1997-01-21
HUT76666A (en) 1997-10-28
BR9508419A (en) 1997-11-18
CA2195665A1 (en) 1996-02-08
CZ19397A3 (en) 1997-06-11
PL318501A1 (en) 1997-06-23
JPH09508140A (en) 1997-08-19
CZ283219B6 (en) 1998-02-18

Similar Documents

Publication Publication Date Title
NO970264L (en) Pharmaceutical compositions comprising a chimeric TNF-binding protein
DE69028671D1 (en) Soluble extracellular fragment of the human IFN-beta 2 / IL-6 receptor, its preparation and pharmaceutical mixture containing this fragment
ATE305798T1 (en) ANTI-TNF ANTIBODIES / TNF RECEPTOR AND METHOTREXATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DE3854741D1 (en) TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS.
KR930702026A (en) Treatment of autoimmune diseases by oral administration of autoantigens
AU4741997A (en) Oral administration of chicken yolk antibodies to treat disease
DK333788A (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF DAMAGED CARTRIC TISSUE
ES2133329T3 (en) VARIANTS OF HUMAN IL-3.
DE58902712D1 (en) N-ACETYL GLUCOSAMINE PREPARATIONS FOR BUCCAL APPLICATION.
DK0668077T3 (en) Products containing G-CSF and TNF-binding protein
NZ335353A (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
AU9363398A (en) Hepatitis c receptor protein cd81
ATE174798T1 (en) THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
KR900011717A (en) Phenylhydrazone, methods for their preparation, and therapeutic and cosmetic compositions prepared therefrom
IT9020968A0 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES
PT874839E (en) DERIVATIVES OF FURANO- AND TIOFENO-CARBOTIAMAMES HIS PREPARATION AND ITS USE AS INHIBITORS OF THE REPLICATION OF HIV-1 AND HIV-1 MUTANTS
IT8026233A0 (en) DERIVATIVE OF N-ACETYL-CYSTEINE WITH THERAPEUTIC ACTIVITY, PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS.
BG92749A (en) AMINOPROPANOL DERIVATIVES, THEIR PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES
WO1997041895A3 (en) TREATMENT OF ASTHMA WITH TNFR-Ig
DK500589A (en) PHARMACEUTICAL PREPARATION FOR TREATMENT OF LUNGE OBSTRUCTIONS
DK452788D0 (en) PAIN PREPARING
NO923078D0 (en) FOOD COMPOSITION FOR PHARMACEUTICAL USE, APPLICATION OF IT AND PROCEDURE FOR TREATMENT
FR2699174B1 (en) Derivatives of 3- (quinoline-6-yl-methyl) -4H-imidazol-4-one, their preparation and their therapeutic use.
ATE211914T1 (en) COMPOSITIONS CONTAINING BISMUTH FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISEASES